Michael J. O’Connell
Impact in
- Oncology top 0.05%
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Screening and Detection
- Pathology and Forensic Medicine top 0.1%
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 100
- Colorectal Cancer Treatments and Studies 45
- Colorectal Cancer Surgical Treatments 43
- Cancer Treatment and Pharmacology 12
-
- Lymphoma Diagnosis and Treatment 20
- Genetic factors in colorectal cancer 18
- Co-authors
- Charles G. Moertel (24 shared papers)Greg Yothers (42 shared papers)Norman Wolmark (32 shared papers)Daniel J. Sargent (39 shared papers)Leonard L. Gunderson (23 shared papers)Larry K. Kvols (8 shared papers)Joseph Rubin (5 shared papers)Linda H. Colangelo (14 shared papers)
- Journals
- Journal of Clinical Oncology (55 papers)Cancer (33 papers)International Journal of Radiation Oncology*Biology*Physics (12 papers)New England Journal of Medicine (9 papers)Clinical Colorectal Cancer (6 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Michael J. O’Connell
225 papers receiving 17.9k citations
Michael J. O’Connell's Hit Papers
Peers
Comparison fields: 5 of 187
- Oncology 9.3k
- Pathology and Forensic Medicine 3.5k
- Cancer Research 1.2k
- Neurology 1.1k
- Pulmonary and Respiratory Medicine 2.4k
Countries citing papers authored by Michael J. O’Connell
This map shows the geographic impact of Michael J. O’Connell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. O’Connell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. O’Connell more than expected).
Fields of papers citing papers by Michael J. O’Connell
This network shows the impact of papers produced by Michael J. O’Connell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. O’Connell. The network helps show where Michael J. O’Connell may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael J. O’Connell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 230 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery Hit paper breakdown → | 1994 | 820 |
| 2 | Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03 Hit paper breakdown → | 2009 | 695 |
| 3 | Treatment of the Malignant Carcinoid Syndrome Hit paper breakdown → | 1986 | 655 |
| 4 | Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Hit paper breakdown → | 1991 | 612 |
| 5 | Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials Hit paper breakdown → | 2005 | 523 |
| 6 | 2009 | 486 | |
| 7 | High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy Hit paper breakdown → | 1985 | 451 |
| 8 | 2001 | 449 | |
| 9 | Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. | 1998 | 444 |
| 10 | Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses Hit paper breakdown → | 2011 | 440 |
| 11 | Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced Cancer Hit paper breakdown → | 1979 | 421 |
| 12 | Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 Hit paper breakdown → | 2010 | 410 |
| 13 | 2004 | 309 | |
| 14 | 2001 | 294 | |
| 15 | 1984 | 290 | |
| 16 | 1992 | 261 | |
| 17 | 2003 | 257 | |
| 18 | 2006 | 253 | |
| 19 | 2012 | 242 | |
| 20 | 2006 | 240 |
About Michael J. O’Connell
Michael J. O’Connell is a scholar working on Oncology, Pathology and Forensic Medicine, Surgery, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 230 papers that have together received 18.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (45 papers), Colorectal Cancer Surgical Treatments (43 papers), Colorectal and Anal Carcinomas (22 papers), Lymphoma Diagnosis and Treatment (20 papers), Genetic factors in colorectal cancer (18 papers), Gastric Cancer Management and Outcomes (14 papers), Cancer Treatment and Pharmacology (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (11 papers). The work is most often cited by research in Oncology (9.3k citations), Pathology and Forensic Medicine (3.5k citations), Cancer Research (1.2k citations), Neurology (1.1k citations) and Pulmonary and Respiratory Medicine (2.4k citations). Michael J. O’Connell has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Charles G. Moertel, Greg Yothers, Norman Wolmark, Daniel J. Sargent, Leonard L. Gunderson, Larry K. Kvols, Joseph Rubin, Linda H. Colangelo, Nicholas J. Petrelli and Daniel G. Haller. Their work appears in journals such as Journal of Clinical Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics, New England Journal of Medicine and Clinical Colorectal Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.